Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Frontiers in Immunology|January 31, 2018
Classic Ulcerative Pyoderma Gangrenosum Is a T Cell-Mediated Disease Targeting Follicular Adnexal Structures: A Hypothesis Based on Molecular and Clinicopathologic StudiesElizabeth A Wang, Andrea Steel, Guillaume Luxardi, et al.
Journal of Autoimmunity|November 30, 2016
CD4+ virtual memory: Antigen-inexperienced T cells reside in the naïve, regulatory, and memory T cell compartments at similar frequencies, implications for autoimmunityAlina I Marusina, Yoko Ono, Alexander A Merleev, et al.
Clinical Immunology (Orlando, Fla.)|August 17, 2021
Glycan biomarkers of autoimmunity and bile acid-associated alterations of the human glycome: Primary biliary cirrhosis and primary sclerosing cholangitis-specific glycansEmanual Maverakis, Alexander A Merleev, Dayoung Park, et al.
The Journal of Investigative Dermatology|January 30, 2023
Cell-Specific and Variant-Linked Alterations in Expression of ERAP1, ERAP2, and LNPEP Aminopeptidases in PsoriasisAlina I Marusina, Antonio Ji-Xu, Stephanie T Le, et al.
Stem Cells (Dayton, Ohio)|October 25, 2019
Tunable hydrogels for mesenchymal stem cell delivery: Integrin-induced transcriptome alterations and hydrogel optimization for human wound healingAlina I Marusina, Alexander A Merleev, Jesus I Luna, et al.
Scientific Reports|October 16, 2020
A site-specific map of the human plasma glycome and its age and gender-associated alterationsAlexander A Merleev, Dayoung Park, Yixuan Xie, et al.
JCI Insight|February 24, 2025
SPP1hi macrophages, NKG7 T cells, CCL5hi fibroblasts, and IgM plasma cells are dominant features of necrobiosisStephanie T Le, Alina I Marusina, Alexander A Merleev, et al.
Nature Communications|September 1, 2023
Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trialArta M Monjazeb, Megan E Daly, Guillaume Luxardi, et al.
Blood Advances|February 24, 2026
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Blood Advances|November 10, 2025
A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative AnalysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Pageof 3